Clinical Trials

Lymphoma, B-Cell, Marginal Zone

NCT02974647 2026-04-22

Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

83 enrolled

Lymphoma, Recurrence

NCT03523975 2026-04-22

Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

28 enrolled

Phase 2 Active not recruiting

Lymphoma, Mantle-Cell

NCT03823534 2026-04-22

Post-Op Pain Control for Prophylactic Intramedullary Nailing.

Phase 3 Recruiting

60 enrolled

LymphoidPlasma cell

Lymphoma, Multiple Myeloma, Pain, Pain, Postoperative

NCT05507541 2026-04-22

TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

10 enrolled

Phase 1 Active not recruiting

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05757700 2026-04-22

Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma

Lymphoma, B-Cell

NCT05858424 2026-04-22

HOPAYA

214 enrolled

Lymphoma, Neoplasms

NCT06839053 2026-04-22

Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT06948786 2026-04-22

Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial

22 enrolled

Lymphoma, Follicular

NCT02553447 2026-04-21

Cholecalciferol in Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia With Vitamin D Deficiency

197 enrolled 15 charts

Lymphoma, Non-Hodgkin, Vitamin D Deficiency, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03595813 2026-04-21

IMMUNO-SUP

135 enrolled

GenitourinaryLymphoid

Lymphoma, Non-Hodgkin, Urologic Neoplasms

NCT03623373 2026-04-21

Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma

Phase 2 Completed

13 enrolled 13 charts

Lymphoma, Mantle-Cell

NCT03919240 2026-04-21

CAR-T Cell Therapy Targeting to CD19 for R/R ALL

196 enrolled

Phase NA Active not recruiting

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04544046 2026-04-21

Supportive Oncology Care At Home RCT

300 enrolled

GastrointestinalHead & NeckLymphoid

Head and Neck Neoplasms, Lymphoma, Pancreatic Neoplasms, Rectal Neoplasms

NCT05646576 2026-04-21

PEACE

LymphoidOther hematologic neoplasmPlasma cell

90 enrolled

Leukemia, Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT05858593 2026-04-21

Positive Youth Development in the Metaverse

32 enrolled 8 charts

Child Behavior, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07137494 2026-04-21

A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)

Phase 1 Recruiting

12 enrolled

Lymphoma, Recurrence

NCT07513129 2026-04-21

Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma

18 enrolled

Phase 3 Active not recruiting

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07541755 2026-04-21

PD1-VEN-CAG

40 enrolled

Phase NA Not yet recruiting

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07542912 2026-04-21

SCENT-3

Lymphoma, Extranodal NK-T-Cell

NCT04544592 2026-04-20

UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL

45 enrolled

Phase 1/2 Active not recruiting

Burkitt Lymphoma, Recurrence, Lymphoma, B-Cell

NCT04939272 2026-04-20

Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

8 enrolled

Lymphoma, Mantle-Cell

NCT04984837 2026-04-20

Study of Lacutamab in Peripheral T-cell Lymphoma

56 enrolled

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT05135351 2026-04-20

Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Cellular Therapy

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT05519579 2026-04-20

Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05848687 2026-04-20

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

90 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05909059 2026-04-20

CAR T-cell Therapy in Patients With Renal Dysfunction

LymphoidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06252675 2026-04-20

Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

Lymphoma, Mantle-Cell

NCT06859008 2026-04-20

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Phase 1 Recruiting

37 enrolled

Phase 2 Not yet recruiting

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT07194980 2026-04-20

Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07222345 2026-04-20

Feasibility of High Intensity Interval Training in Survivors of Childhood, Adolescent, and Young Adult Hodgkin Lymphoma

Phase 1/2 Not yet recruiting

Hodgkin Disease

NCT07283679 2026-04-20

Phase I/II Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma

Phase 1/2 Not yet recruiting

Lymphoma, B-Cell

NCT07313852 2026-04-20

A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia

26 enrolled

Burkitt Lymphoma

NCT07539610 2026-04-20

Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors

9 enrolled

Burkitt Lymphoma, Lymphoma

NCT07539688 2026-04-20

Phase I Clinical Study on the Safety and Efficacy of CY-219 CAR-T Cell Injection in the Treatment of Relapsed/Refractory B-Cell Lymphoma

18 enrolled

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT03341520 2026-04-17

GAZAI

Phase 2 Completed

89 enrolled

Lymphoma, Follicular

NCT03536975 2026-04-17

CAREGIVERSPRO

48 enrolled

Phase EARLY_PHASE1 Active not recruiting

Dementia, Lymphoma, Follicular, Cognitive Dysfunction

NCT04134325 2026-04-17

Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma

10 enrolled

Hodgkin Disease

NCT04996160 2026-04-17

Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia

Phase 1 Completed

2 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05983965 2026-04-17

Study of Tazemetostat in Lymphoid Malignancies

Phase 1 Terminated

6 enrolled

Phase 2 Not yet recruiting

Leukemia, Lymphoma, Lymphoma, T-Cell

NCT07453095 2026-04-17

Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy

41 enrolled

Recurrence, Lymphoma, Mantle-Cell

NCT07528352 2026-04-17

REBEL

12 enrolled

Phase 1/2 Not yet recruiting

Lymphoma, Large B-Cell, Diffuse

NCT07535710 2026-04-17

Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma

37 enrolled

DermatologicLymphoid

Recurrence, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT07535762 2026-04-17

Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma

Phase 2 Not yet recruiting

36 enrolled

Phase 1/2 Active not recruiting

Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

NCT00466531 2026-04-16

Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

50 enrolled

Phase 2 Active not recruiting

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02131584 2026-04-16

Ruxolitinib Phosphate in Reducing Fatigue in Patients With Chronic Lymphocytic Leukemia

10 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03418038 2026-04-16

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

80 enrolled

Hodgkin Disease, Lymphoma, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse

NCT03618550 2026-04-16

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

257 enrolled

Phase 2 Active not recruiting

Hodgkin Disease, Recurrence

NCT04189757 2026-04-16

Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma

9 enrolled